Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INBRX-106 + Pembrolizumab in Stage II/III TNBC
NCT06353997Phase 2Recruiting
- Start
- Sep 2024
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of inbrx-106 in triple-negative breast cancer (TNBC). Started Sep 2024; status: recruiting.
02
Drugs
inbrx-106
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06353997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06353997.